April 16, 2014
Kolltan adds board members
Kolltan Pharmaceuticals, which raised $60 million last month, has added two new board members, it announced.
The New Haven biopharmaceutical company, which is privately held, said Dr. Daniel R. Vlock and William S. Slattery have joined the board.
Vlock is a medical oncologist who has directed cancer drug development programs. He is CEO of Alopexx Enterprises LLC and Alopexx Pharmaceuticals, which licensed an antibody to Sanofi-Aventis.
Slattery will be an observer for Deerfield Management, which participated in the Series D round last month.
Most Recent
Most Recent
0 Comments